Six (or more) drugs in search of a mechanism: DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 4, Issue 1, 2006, Pages 83-90

  Gore, Steven D ^a,b  

^a Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ^*  (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Chromatin; Epigenetics; Gene silencing; Histone deacetylase; Methyltransferase; Myelodysplastic syndromes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ARYLBUTYRIC ACID DERIVATIVE; AZACITIDINE; BUTYRIC ACID; DNA METHYLTRANSFERASE INHIBITOR; FR 901228; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; IMATINIB; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P15; RETINOIC ACID; RITUXIMAB; VALPROIC ACID; ANTINEOPLASTIC ANTIMETABOLITE; DNA METHYLTRANSFERASE; ENZYME INHIBITOR; HISTONE DEACETYLASE;

ACUTE GRANULOCYTIC LEUKEMIA; CLINICAL TRIAL; CYTOPENIA; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; EPIGENETICS; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENOME; HEMATOLOGIC MALIGNANCY; HUMAN; MAXIMUM ALLOWABLE CONCENTRATION; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NONHUMAN; PROMYELOCYTIC LEUKEMIA; PROTEIN METHYLATION; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; DRUG ANTAGONISM; GENETIC EPIGENESIS; GENETICS;

ANTIMETABOLITES, ANTINEOPLASTIC; DNA MODIFICATION METHYLASES; ENZYME INHIBITORS; EPIGENESIS, GENETIC; HISTONE DEACETYLASES; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 33645083241     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2006.0009     Document Type: Review

References (54)

1. Jones PA, Baylin SR. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-428.
2. Rice JC, Allis CD. Code of silence. Nature 2001;414:258-261.
3. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549-557.
4. Von Hoff DD, Slavik M, Muggia FM. 5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia. Ann Intern Med 1976;85:237-245.
5. Momparler RL, Bouchard J, Onetto N, et al. 5-aza-2′-deoxycytidine therapy in patients with acute leukemia inhibits DNA methylation. Leuk Res 1984;8:181-185.
6. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980;20:85-93.
7. Schmelz K, Sattler N, Wagner M, et al. Induction of gene expression by 5-Aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms. Leukemia 2005;19:103-111.
8. Schmelz K, Wagner M, Dorken B, Tamm I. 5-Aza-2′-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. Int J Cancer 2005;114:683-695.
9. Schneider-Stock R, Diab-Assef M, Rohrbeck A, et al. 5-Aza-cytidine is a potent inhibitor of DNA methyltransterase 3a and induces apoptosis in HCT-116 colon cancer cells via Gadd45 and p53-dependent mechanisms. J Pharmacol Exp Ther 2005;312:525-536.
10. Zhu WG, Hileman T, Ke Y, et al. 5-aza-2′-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. J Biol Chem 2004;279:15161-15166.
11. Charache S, Dover G, Smith K, et al. Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta globin gene complex. Proc Natl Acad Sci USA 1983;80:4842-4846.
12. Dover G, Charache S, Boyer SH, et al. 5-azacytidine increased HbF production and reduces anemia in sickle cell disease. Dose-response analysis of subcutaneous and oral dosing regimens. Blood 1985; 66:532.
13. Ley T, DeSimone J, Anagnou NP, et al. 5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. N Engl J Med 1982;307:1469-1475.
14. Silverman LR, Holland JF, Weinberg RS, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 1993; 7[suppl 1]:21-29.
15. Silverman L, Holland JF, Demakos EP, et al. Azacitidine in myelodysplastic syndromes: CALGB studies 8421 and 8921. Ann Hematol 1994;68.
16. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429-2440.
17. Kornblith AB, Herndon JE, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 2002;20:2441-2452.
18. Wijermans PW, Krulder JW, Huijgens PC, et al. Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 1997;11[suppl 1]:19-23.
19. Wijermans P, Lubbert M, Verhoef G, et al. Low-dose 5-aza-2′- deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000;18:956-962.
20. Lubbert M, Wijermans P, Kunzmann R, et al. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br J Haematol 2001;114:349-357.
21. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
22. Saba HI, Wijermans PW. Decitabine in myelodysplastic syndromes. Semin Hematol 2005;42[2 suppl 2]:23-31.
23. Kantarjian HM, Issa JP. Decitabine dosing schedules. Semin Hematol 2005;42[suppl 2]:17-22.
24. Plagemann PG, Behrens M, Abraham D. Metabolism and cytotoxicity of 5-azacytidine in cultured Novikoff rat hepatoma and P388 mouse leukemia cells and their enhancement by preincubation with pyrazofurin. Cancer Res 1978;38:2458-2466.
25. Rudek MA, Zhao M, He P, et al. Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol 2005;23:3906-3911.
26. Marcucci G, Silverman L, Eller M, et al. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol 2005;45:597-602.
27. Daskalakis M, Nguyen TT, Nguyen C, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 2002;100:2957-2964.
28. Cameron EE, Baylin SB, Herman JG. P15INK4b CpG island methylation is heterogeneous in primary acute leukemia and suggests density as a critical factor in transcriptional silencing. Blood (in press).
29. Herman JG, Civin CI, Issa JP, et al. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cane Res 1997;57:837-841.
30. Herman JG, Jen J, Merlo A, et al. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15(INK4B). Cancer Res 1996;56:722-727.
31. Quesnel B, Guillerm G, Vereecque R, et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998;91:2985-2990.
32. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004;103:1635-1640.
33. Yang AS, Estecio MR, Doshi K, et al. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 2004;32:e38.
34. Mund C, Hackanson B, Stresemann C, et al. Characterization of DNA demethylation effects induced by 5-Aza-2′-deoxycytidine in patients with myelodysplastic syndrome. Cancer Res 2005;65:7086-7090.
35. Rosato RR, Grant S. Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets 2005;9:809-824.
36. Novogrodsky A, Dvir A, Ravid A, et al. Effect of polar organic compounds on leukemic cells. Butyrate-induced partial remission of acute myelogenous leukemia in a child. Cancer 1983;51:9-14.
37. Gore SD, Samid D, Weng LJ. Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells. Clin Cancer Res 1997;3:1755-1762.
38. DiGiuseppe JA, Weng LJ, Yu KH, et al. Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: Structure-Function Analysis. Leukemia 1999;13:1243-1253.
39. Gore SD, Weng LJ, Zhai S, et al. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 2001;7:2330-2339.
40. Yu KH, Weng LJ, Fu S, Gore SD. Augmentation of phenylbutyrate-induced differentiation of myeloid leukemia cells using all trans-retinoic acid. Leukemia 2000;13:1258-1265.
41. Gore SD, Weng LJ, Figg WD, et al. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 2002;8:963-970.
42. Gottlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001;20:6969-6978.
43. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 2004;64:1079-1086.
44. Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004;104:1266-1269.
45. Gore SD, Carducci MA. Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Experr Opin Invest Drugs 2000;9:2923-2934.
46. Minucci S, Pelicci PG. Retinoid receptors in health and disease: co-regulators and the chromatin connection. Semin Cell Dev Biol 1999;10:215-225.
47. Breitman TR, He R. Combinations of retinoic acid with either sodium butyrate, dimethyl sulfoxide, or hexamethylene bisacetamide synergistically induce differentiation of the human myeloid leukemia cell line HL60. Cancer Res 1990;60:6268-6273.
48. Trus MR, Yang L, Suarez SF, et al. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells. Leukemia 2005;19:1161-1168.
49. Warrell RP Jr, He LZ, Richon V, et al. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. JNCI 1998;90:1621-1625.
50. Raffoux E, Chaibi P, Dombret H, Degos L. Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. Haematologica 2005;90:986-988.
51. Pilatrino C, Cilloni D, Messa E, et al. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. Cancer 2005;104:101-109.
52. Nan X, Ng HH, Johnson CA, et al. Transcriptional repression by the methyl-CpG-binding protein MeCPZ involves a histone deacetylase complex. Nature 1998;393:386-389.
53. Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature Genet 1999;21:103-107.
54. Garcia-Manero G, Gore SD, Future directions for the use of hypomethylating agents. Semin Hematol 2005;42(suppl 2):50-59.